SILO PHARMA, INC. FDIC Indemnification Asset, Cash Payments Received
SILO PHARMA, INC. (SILO) reported FDIC Indemnification Asset, Cash Payments Received of $4.16 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-12.
Discontinued › Notes › Financial Services › Banking and Thrift
us-gaap:FDICIndemnificationAssetCashPaymentsReceived · last filed 2023-11-13
- SILO PHARMA, INC. fdic indemnification asset, cash payments received for the quarter ending 2023-03-31 was $4.16M, a 51.59% decline year-over-year.
- SILO PHARMA, INC. fdic indemnification asset, cash payments received for the quarter ending 2022-12-31 was -$882.00K.
- SILO PHARMA, INC. fdic indemnification asset, cash payments received for the quarter ending 2022-09-30 was $3.51M, a 41.52% decline year-over-year.
- SILO PHARMA, INC. fdic indemnification asset, cash payments received for the quarter ending 2022-06-30 was -$360.00K.
- SILO PHARMA, INC. fdic indemnification asset, cash payments received for fiscal 2021 was $9.10M, a 934.09% increase from fiscal 2020.
- SILO PHARMA, INC. fdic indemnification asset, cash payments received for fiscal 2020 was $880.00K.
- SILO PHARMA, INC. fdic indemnification asset, cash payments received for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- SILO PHARMA, INC. fdic indemnification asset, cash payments received for fiscal 2018 was $86.70K, a 94.39% increase from fiscal 2017.
| Period end | FDIC Indemnification Asset, Cash Payments Received 3 month | FDIC Indemnification Asset, Cash Payments Received 6 month | FDIC Indemnification Asset, Cash Payments Received 9 month | FDIC Indemnification Asset, Cash Payments Received 12 month |
|---|---|---|---|---|
| 2023-03-31 | $4.16M 10-Q · filed 2023-05-12 | $3.28M derived: sum of 2 quarters · filed 2023-11-13 | $6.79M derived: sum of 3 quarters · filed 2023-11-13 | $6.43M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | -$882.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2023-11-13 | $2.63M derived: sum of 2 quarters · filed 2023-11-13 | $2.27M derived: sum of 3 quarters · filed 2023-11-13 | $10.87M 10-Q · filed 2023-11-13 |
| 2022-09-30 | $3.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.15M derived: sum of 2 quarters · filed 2022-11-10 | $11.75M 10-Q · filed 2022-11-10 | $11.05M derived: sum of 4 quarters · filed 2023-03-24 |
| 2022-06-30 | -$360.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $8.24M 10-Q · filed 2022-08-01 | $7.54M derived: sum of 3 quarters · filed 2023-03-24 | $13.54M derived: sum of 4 quarters · filed 2023-03-24 |
| 2022-03-31 | $8.60M 10-Q · filed 2022-05-13 | $7.90M derived: sum of 2 quarters · filed 2023-03-24 | $13.90M derived: sum of 3 quarters · filed 2023-03-24 | $13.31M derived: sum of 4 quarters · filed 2023-03-24 |
| 2021-12-31 | -$700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $5.30M derived: sum of 2 quarters · filed 2023-03-24 | $4.71M derived: sum of 3 quarters · filed 2023-03-24 | $9.10M 10-K · filed 2023-03-24 |
| 2021-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $5.41M derived: sum of 2 quarters · filed 2021-11-10 | $9.80M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$590.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $3.80M 10-Q · filed 2021-08-13 | ||
| 2021-03-31 | $4.39M 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $880.00K 10-K · filed 2022-03-28 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $0.00 derived: sum of 2 quarters · filed 2020-03-20 | $0.00 derived: sum of 3 quarters · filed 2020-03-20 | $0.00 10-K · filed 2020-03-20 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $0.00 derived: sum of 2 quarters · filed 2019-11-13 | $0.00 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $0.00 10-Q · filed 2019-08-13 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-14 | |||
| 2018-12-31 | $86.70K 10-K · filed 2020-03-20 | |||
| 2017-12-31 | $44.60K 10-K · filed 2019-04-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |